| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human BCL2L12 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与BCL2L12抗体相关的文献摘要信息，供参考：
---
1. **文献名称**: *BCL2L12 mediates resistance to apoptosis in glioblastoma*
**作者**: Stegh AH, et al.
**摘要**: 研究揭示了BCL2L12在胶质母细胞瘤(GBM)中通过抑制caspase-7活性调控细胞凋亡的机制。研究中开发了针对BCL2L12蛋白的单克隆抗体，并通过免疫印迹和免疫组化验证其在肿瘤组织中的高表达，表明其可作为治疗靶点。
---
2. **文献名称**: *BCL2L12 as a prognostic marker in colorectal cancer*
**作者**: Floros KV, et al.
**摘要**: 该研究评估了BCL2L12在结直肠癌中的表达及其与预后的相关性。利用特异性抗体进行免疫组织化学分析，发现BCL2L12高表达与患者生存期缩短显著相关，提示其可能作为临床预后标志物。
---
3. **文献名称**: *BCL2L12 modulates p53-dependent apoptosis in breast cancer*
**作者**: Kontos CK, et al.
**摘要**: 研究探讨了BCL2L12在乳腺癌中通过调控p53信号通路影响细胞凋亡的作用。通过Western blot和免疫荧光技术(使用兔多克隆抗体)证实BCL2L12与p53的直接结合，为靶向治疗提供依据。
---
4. **文献名称**: *Antibody-based detection of BCL2L12 isoforms in human cancers*
**作者**: Papageorgiou SG, et al.
**摘要**: 研究开发了一种特异性识别BCL2L12不同剪接变体的抗体，并验证其在肺癌、前列腺癌中的表达差异。抗体在ELISA和流式细胞术中表现高特异性，为癌症分型提供了新工具。
---
以上文献聚焦于BCL2L12抗体的开发、验证及其在肿瘤机制与诊断中的应用。如需具体文献来源，可进一步通过PubMed或期刊数据库检索作者及标题获取全文。
The BCL2L12 (B-cell lymphoma 2-like 12) gene encodes a member of the BCL-2 protein family, which regulates apoptotic pathways by modulating mitochondrial membrane permeability and caspase activation. Discovered in 2002. BCL2L12 is unique among BCL-2 proteins due to its dual role in apoptosis, exhibiting both anti- and pro-apoptotic functions depending on cellular context, post-translational modifications, and interactions with other proteins. It is highly expressed in the brain, testes, and certain cancers, including glioblastoma, colorectal carcinoma, and breast cancer. In glioblastoma, BCL2L12 is associated with tumor aggressiveness and resistance to therapy, partly through its ability to inhibit caspase-7 and bind p53. thereby impairing apoptosis and promoting tumor survival.
BCL2L12 antibodies are critical tools for studying its expression, localization, and interactions in both physiological and pathological settings. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues or cell lines. Commercially available antibodies often target specific epitopes, such as the N-terminal or C-terminal regions, to ensure specificity. Researchers also utilize BCL2L12 antibodies to explore its potential as a diagnostic or prognostic biomarker in cancer, given its overexpression in malignancies and role in therapy resistance. However, antibody validation remains essential due to homology with other BCL-2 family members and splice variants. Understanding BCL2L12's complex biology through these reagents may inform therapeutic strategies targeting apoptotic dysregulation in cancer.
×
